Poniard Pharmaceuticals, Inc.
PARD
Rank in Stocks
#35290
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Share Price
$0.0001
Last synced: 2026-11-06
Market Cap
$150.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Poniard Pharmaceuticals, Inc. (PARD)
Category
Healthcare
EPS for Poniard Pharmaceuticals, Inc. (PARD)
EPS as of September 2011 TTM: $-11.69
According to Poniard Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-11.69. At the end of 2010 the company had an EPS of $-26.40, an increase over its 2009 EPS of $-52.40.
EPS history for Poniard Pharmaceuticals, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-11.69 | -55.72% |
| 2010 | $-26.40 | -49.62% |
| 2009 | $-52.40 | -7.09% |
| 2008 | $-56.40 | 30.56% |
| 2007 | $-43.20 | -21.17% |
| 2006 | $-54.80 | -64.23% |
| 2005 | $-153.20 | -3.26% |
| 2004 | $-158.37 | 135.70% |
| 2003 | $-67.19 | -68.54% |
| 2002 | $-213.56 | -3.26% |
| 2001 | $-220.76 | 84.00% |
| 2000 | $-119.98 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -233.96% |
US
|
|
| $-7.07 | -39.52% |
US
|
|
| $-5.29 | -54.75% |
AU
|
|
| $12.88 | -210.18% |
BE
|
|
| $21.56 | -284.43% |
NL
|
Questions about Poniard Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Poniard Pharmaceuticals, Inc.'s earnings per share (EPS)?
Poniard Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-11.69, as of Sep 2011.
What was Poniard Pharmaceuticals, Inc.'s earnings per share (EPS) in 2010?
In 2010, Poniard Pharmaceuticals, Inc.'s earnings per share (EPS) was $-26.40, compared with $-52.40 in 2009.
How has Poniard Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2005?
From 2005 to 2010, Poniard Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2010 ($-26.40) and lowest in 2005 ($-153.20).
How does Poniard Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Poniard Pharmaceuticals, Inc.'s earnings per share (EPS) ($-11.69) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.